Technology | ECG | August 13, 2015

iWorx Systems Inc. Introduces Zebrafish ECG Recording and Analysis System

Zebrafish ECG data a major driver of cardiac research

zebrafish, iWorx Systems Inc., ZS-200 Zebrafish ECG System, cardiac research

August 13, 2015 — iWorx Systems Inc., developer of advanced physiology teaching and research instruments and software, has introduced a compact, non-invasive system (patent pending) for recording and analyzing electrocardiogram (ECG) data from zebrafish.

The iWorx ZS-200 Zebrafish ECG System includes a high-resolution, low-noise single-channel recorder optimized for recording microvolt ECG signals. The system also comes complete with a recording chamber, fish pedestal, Ag/AgCl electrodes, cable assembly and iWorx LabScribe3 recording software with the ECG Analysis Module.

iWorx LabScribe ECG Analysis Module automates the analysis of ECG data. Specific analysis templates are included to accurately delineate PQRST onset, durations and amplitudes. Custom templates can also be created based on unique ECG profiles and saved to a library for future use.

Other features include beat averaging, beat classification, outlier removal, Pointcaré plots, scattergrams and the ability to easily extract source data and average data as images or text files. Also included is a comprehensive list of 24 calculations including R-R, PR, QT, QR and QTc intervals, QRS, T, P and TP durations, P, Q, R, S, T amplitudes and ST elevation.

For more information: www.iworx.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Overlay Init